- |||||||||| levetiracetam / Generic mfg., levetiracetam low dose (AGB101) / AgeneBio
[VIRTUAL] A randomized controlled trial measuring changes in cerebral blood flow after Levetiracetam in patients with Alzheimers disease () - Aug 2, 2020 - Abstract #AAIC2020AAIC_3362;
One possible explanation could be that in mild AD, epileptic activity in the hippocampus leads to an excessive inhibition, and so relieving the inhibition with levetiracetam leads to an increased blood flow. These findings provide evidence of a potential beneficial effect of levetiracetam in patients with Alzheimers disease, but larger studies are needed, particularly with longer dosage schedules to determine whether there are any clinical improvements.
- |||||||||| levetiracetam low dose (AGB101) / AgeneBio
Trial completion date, Trial suspension, Trial primary completion date: Network-Level Mechanisms for Preclinical Alzheimer's Disease Development (clinicaltrials.gov) - Jul 13, 2020
P2, N=50, Suspended,
These findings provide evidence of a potential beneficial effect of levetiracetam in patients with Alzheimers disease, but larger studies are needed, particularly with longer dosage schedules to determine whether there are any clinical improvements. Trial completion date: Mar 2020 --> Mar 2021 | Recruiting --> Suspended | Trial primary completion date: Mar 2020 --> Mar 2021
- |||||||||| Vimpat (lacosamide) / UCB, Daiichi Sankyo, levetiracetam / Generic mfg., levetiracetam low dose (AGB101) / AgeneBio
Retrospective data, Journal, Monotherapy: Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. (Pubmed Central) - Jul 4, 2020
In this retrospective real-life study, the efficacy and the tolerability of LCM as monotherapy was favorable even at low doses in older patients and comparable with LEV with a high rate of long-term seizure freedom. Considering the frequent comorbidities and the risk of drug-drug interactions, LCM monotherapy may be a valuable option in elderly patients with focal onset epilepsy because of its favorable pharmacokinetic profile.
- |||||||||| levetiracetam low dose (AGB101) / AgeneBio
Trial completion date, Trial primary completion date: Hope4MCI: Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (clinicaltrials.gov) - Apr 3, 2020
P3, N=830, Recruiting,
The efficacy of very- low dose AED needs to be investigated even if this strategy seems to be relevant for fragile patients. Trial completion date: Nov 2022 --> Mar 2023 | Trial primary completion date: Nov 2021 --> Sep 2022
- |||||||||| levetiracetam low dose (AGB101) / AgeneBio
Clinical, Journal: Clinical Use and Efficacy of Levetiracetam for Absence Epilepsies. (Pubmed Central) - Mar 26, 2020
When effective, levetiracetam can control absence epilepsy at a relatively low dose. Lack of seizure control requiring continued dose escalation should prompt early consideration of a therapeutic medication transition.
- |||||||||| tacrolimus / Generic mfg.
Clinical, Journal: Clinical Pharmacometrics for Rational Drug Treatment (Pubmed Central) - Mar 12, 2020
Pharmacokinetic and pharmacodynamic models were successfully built using electronic medical information to explain retrospective international normalized ratio values of prothrombin time before and after catheter ablation in warfarin-treated patients...A physiologically based pharmacokinetic model adapted to tacrolimus pharmacokinetic data in patients who underwent living-donor liver transplantation was constructed, and clarified that oral clearance of this drug was affected by CYP3A5 genotypes in both the liver and intestine to the same extent. In conclusion, pharmacometrics is a useful methodology for individualized and optimized drug therapy.
- |||||||||| Vimpat (lacosamide) / UCB, levetiracetam / Generic mfg., levetiracetam low dose (AGB101) / AgeneBio
[VIRTUAL] Peri-ictal psychosis associated with neurocysticercosis: a case report. (All Screens in Poster Area) - Feb 20, 2020 - Abstract #EPA2020EPA_1330;
The diagnosis of psychotic states associated with epilepsy could be difficoult because of the very different clinical manifestations and. It is important to consider the high prevalence of psychiatric comorbility in patients with epilepsy to administer them a multidisciplinary treatment.
- |||||||||| lacosamide / Generic mfg., levetiracetam / Generic mfg., levetiracetam low dose (AGB101) / AgeneBio
Second-Line Anti-Seizure Medication Dosing in Pediatric Refractory Convulsive Status Epilepticus (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_959;
If a patient was > 50kg, we considered 1000mg as the minimum dose (for all ASM, except for lacosamide –LAC-)...Reasons of dividing doses may include medical concerns related to clinical presentation or potential side effects. At times, treatment times exceeded optimal medication application, and analysis of factors related to treatment timing is ongoing to tailor respective interventions.
- |||||||||| methylprednisolone / Generic mfg., Rituxan (rituximab) / Roche, Biogen
Improvement of Cognition, Parkinsonism and Faciobrachial Dystonic Seizures with Immunosuppression in LGI1 Encephalitis (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_899;
A 5 day course of IV methylprednisolone resulted in a marked seizure improvement and cognitive/mobility gains...The patient continued on prednisone infusions weekly as bridge to rituximab for long term therapy...Early initiation of immunotherapy may prevent development of cognitive decline and improve long-term outcomes. Parkinsonian features of this patient may further implicate basal ganglia dysfunction in this autoimmune disorder, though future studies will be needed.
- |||||||||| pregabalin / Generic mfg.
A Case of Pregabalin-Induced Myoclonic Status Epilepticus (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_609;
Patient should be counseled accordingly and PGB withdrawn if MSE should occur. Additional research is needed to determine how PGB can evoke MSE.
- |||||||||| levetiracetam / Generic mfg., clobazam / Generic mfg., levetiracetam low dose (AGB101) / AgeneBio
Adult-Onset Visually Provoked Myoclonic Epilepsy (Hall E) - Nov 28, 2019 - Abstract #AES2019AES_395;
Video EEG monitoring was necessary for correct diagnosis. Our patient had no response to Levetiracetam and complete response to low-dose Clobazam, suggesting a benzodiazepine responsive syndrome.
- |||||||||| levetiracetam / Generic mfg., levetiracetam low dose (AGB101) / AgeneBio
NEURONAL PENTRAXIN 2: BIOMARKER AND MECHANISM ACROSS THE AGING/ALZHEIMER’S SPECTRUM. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_297;
P3
Notably, an increase in NPTX2 produced by low dose levetiracetam administration may contribute to the reduction of neural overactivity and cognitive improvement previously reported with this aged rat model of memory impairment (Koh et al. 2010; Haberman et al.
- |||||||||| Preclinical, Journal: Evaluation of antiseizure drug efficacy and tolerability in the rat lamotrigine-resistant amygdala kindling model. (Pubmed Central) - Aug 24, 2019
Ezogabine and valproate were also highly effective, whereas topiramate and levetiracetam were not effective at the doses tested. These results strengthen the conclusion that the lamotrigine-resistant amygdala kindling model demonstrates pharmacoresistance to certain ASDs, including, but not limited to, sodium channel blockers, and supports the utility of the model for helping to identify compounds with potential efficacy against pharmacoresistant seizures.
- |||||||||| levetiracetam low dose (AGB101) / AgeneBio
Trial primary completion date: Network-Level Mechanisms for Preclinical Alzheimer's Disease Development (clinicaltrials.gov) - Feb 12, 2019
P2, N=50, Recruiting,
Patients receiving pregabalin, tiagabine, and vigabatrin had the highest odds of ≥50% reduction in seizures, and patients receiving ezogabine, levetiracetam, and vigabatrin had the highest odds of seizure freedom. Trial primary completion date: Mar 2019 --> Mar 2020
|
